Mid-Day Market Update: Tocagen Falls On Failed Late-Stage Brain Cancer Study; Sintx Technologies Shares Jump
|Midway through trading Thursday, the Dow traded up 0.42% to 27,251.73 while the NASDAQ rose 0.41% to 8,203.22. The S&P also rose, gaining 0.40% to 3,012.91.
Leading and Lagging Sectors
Consumer discretionary shares climbed 0.8% on Thursday. Meanwhile, top gainers in the sector included Ruhnn Holding Limited RUHN 28.35%, up 37%, and LKQ Corporation LKQ 10.37%, up 10%.
In trading on Thursday, energy shares fell 0.6%.
Top Headline
Kroger Co KR 0.92% reported better-than-expected earnings for its second quarter, while sales missed views.
Second-quarter earnings came in at 44 cents per share, beating estimates of 41 cents. Sales came in at $28.17 billion, versus estimates by $28.38 billion.
Kroger plans to continue to reduce costs and says it is on track to deliver $100 million in incremental operating profit through alternative profit stream growth. Kroger maintained its 2019 outlook.
Equities Trading UP
Sintx Technologies, Inc. SINT 60% shares shot up 69% to $2.5404 after Ascendiant Capital initiated coverage on the stock with a Buy rating and a $3 price target.
Shares of 111, Inc. YI 26.09% got a boost, shooting up 18% to $5.41. 111 reported the signing of a strategic cooperation agreement with Dong-E-E-Jiao Co., Ltd. for direct sourcing.
10x Genomics, Inc. TXG shares were also up, gaining 42% to $55.35. 10x Genomics priced IPO of 10 million shares at $39 per share.
Equities Trading DOWN
Tocagen Inc. TOCA 77.27% shares tumbled 77% to $0.9510 following an adverse clinical trial readout. Tocagen, a thinly traded nano-cap biotech, said Thursday morning a Phase 3 TOCA 5 study evaluating Toca 511 and Toca FC in patients with recurrent, high-grade glioma undergoing resection missed the primary endpoint of overall survival compared to the standard of care.
Shares of Adverum Biotechnologies, Inc. ADVM 33.83% were down 30% to $8.41 after the company reported data from the first cohort of OPTIC phase 1 trial of ADVM-022 intravitreal gene therapy to treat wet AMD.
Tailored Brands, Inc. TLRD 25.24% was down, falling 27% to $5.26 after the company issued Q3 EPS guidance below analyst estimates. The company also suspended its quarterly dividend.
Commodities
In commodity news, oil traded down 1.8% to $54.73, while gold traded up 0.5% to $1,510.70.
Silver traded down 0.1% Thursday to $18.16, while copper rose 0.8% to $2.635.
Euro zone
European shares were higher today. The eurozone’s STOXX 600 rose 0.2%, the Spanish Ibex Index rose 0.25%, while Italy’s FTSE MIB Index rose 0.88%. Meanwhile, the German DAX rose 0.41% and the French CAC 40 climbed 0.44% while UK shares rose 0.09%.
Economics
The Consumer Price Index rose 0.1% for August, versus economists’ expectations for a 0.1% increase.
U.S. initial jobless claims fell 15,000 to 204,000 for the latest week. However, analysts were expecting a 215,000 reading.
Domestic supplies of natural gas climbed 78 billion cubic feet for the week ended September 6, the U.S. Energy Information Administration reported. However, analysts projected a gain of 87 billion cubic feet.
The U.S. Treasury budget report for August will be released at 2:00 p.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.